BioLargo Reports Third Quarter 2026 Results, Forecasting Commercial Breakout in 2027
BioLargo, Inc. (BLGO) reported Q3 2026 results with revenue at $1.09M, down 1% YoY, and net loss at $3.82M, down 47% YoY. Clyra Medical, a subsidiary, drove 57% of the nine-month net loss. The company launched consumer products under the 'barebird' brand and is preparing for a 2027 product line rollout. BioLargo's AEC PFAS treatment is being validated and has seen increased interest from potential partners.
